New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
06:08 EDTACHNAchillion announces clinical results for ACH-3102
Achillion announced updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 including subjects who had Y93 mutations at baseline. A second oral presentation on ACH-3102 was made at APASL 2014 that discussed clinical virology and the lack of virologic breakthrough that was observed in the novel Phase 2 clinical trial evaluating ACH-3102 with ribavirin for patients with treatment-na´ve genotype 1b HCV. Despite the presence of up to six linked mutations identified at baseline in the NS5A protein, ACH-3102, without the co-administration of interferon or a second direct-acting antiviral, was able to suppress viral replication with no virologic breakthrough observed during 12 weeks of treatment.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
09:37 EDTACHNBarclays healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
April 26, 2015
15:07 EDTACHNAchillion reports results for ACH-3102, ACH-3422, says supports further study
Subscribe for More Information
April 24, 2015
12:22 EDTACHNAchillion spokesperson says EASL presentation not canceled, Bloomberg reports
Subscribe for More Information
11:22 EDTACHNAchillion strength attributed to rumor of canceling presentation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use